Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
29 avr. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
03 avr. 2019 16h00 HE
|
Merus N.V.
UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,...
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
08 janv. 2018 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
11 déc. 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
22 mai 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...
Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
01 mai 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc, a next-generation antibody therapeutics company, announced today at the Protein Engineering Summit (PEGS) in Boston the discovery...
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
13 févr. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
04 janv. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
29 nov. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent Safety and Target Engagement Established for Anti-RSPO3 REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) --...
OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09 nov. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...